The role of microvesicles in tissue repair

Microvesicles (MVs) are released by almost all cells in resting and activated conditions. First described several years ago, it is only recently that their mechanisms of action are being elucidated, and their potential role in health and disease is drawing increasing attention. The main function of MVs is signaling through specific interactions with target cells and the transferring of gene products. Gaining further insights into the molecular specificity of MVs has allowed identification of the cellular source and may provide new diagnostic tools in the future. Indeed, an increasing body of evidence indicates that MVs are capable of mediating tissue repair in models of acute kidney and liver injury. In this review, we will discuss the mechanisms through which MVs from stem cells may act on target cells and may modify the response to injury. Furthermore, MVs from inflammatory cells are suspected to be involved in various diseases, such as cardiovascular and renal diseases, pathological pregnancy, tumors and sepsis. MVs are no doubt also involved in modulating immunity, and future studies will clarify their functional role in negatively modulating the cell response. Their role in physiological and pathological processes is increasingly appreciated. Depending on the cell source and the condition, MVs may be either beneficial or detrimental to the host. The recognition of their pathogenetic role may suggest new approaches to future therapies.

[1]  G. Camussi,et al.  Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  N. Ohkohchi,et al.  Platelet Administration Via the Portal Vein Promotes Liver Regeneration in Rats After 70% Hepatectomy , 2011, Annals of surgery.

[3]  D. Miao,et al.  Transplanted Human Amniotic Membrane-Derived Mesenchymal Stem Cells Ameliorate Carbon Tetrachloride-Induced Liver Cirrhosis in Mouse , 2011, PloS one.

[4]  N. Perico,et al.  Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[5]  Li Yan,et al.  The significance of CD14+ monocytes in peripheral blood stem cells for the treatment of rat liver cirrhosis. , 2010, Cytotherapy.

[6]  Matthew K. Knabel,et al.  Stem Cell Mobilization Is Life Saving in an Animal Model of Acute Liver Failure , 2010, Annals of surgery.

[7]  Luca Sterpone,et al.  Microvesicles Derived from Adult Human Bone Marrow and Tissue Specific Mesenchymal Stem Cells Shuttle Selected Pattern of miRNAs , 2010, PloS one.

[8]  P. Thorner,et al.  Angiomyeloproliferative lesions following autologous stem cell therapy. , 2010, Journal of the American Society of Nephrology : JASN.

[9]  P. Quesenberry,et al.  Stem cell plasticity revisited: the continuum marrow model and phenotypic changes mediated by microvesicles. , 2010, Experimental hematology.

[10]  Liyong Pu,et al.  Antifibrotic effect of hepatocyte growth factor-expressing mesenchymal stem cells in small-for-size liver transplant rats. , 2010, Stem cells and development.

[11]  C M Habibullah,et al.  Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. , 2010, Cell transplantation.

[12]  G. Camussi,et al.  The dynamic stem cell microenvironment is orchestrated by microvesicle-mediated transfer of genetic information. , 2010, Histology and histopathology.

[13]  G. Camussi,et al.  Use of a rotary bioartificial liver in the differentiation of human liver stem cells. , 2010, Tissue engineering. Part C, Methods.

[14]  G. Camussi,et al.  Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information , 2010, Current opinion in nephrology and hypertension.

[15]  M. Shimizu,et al.  Mesenchymal Stem Cells Attenuate Renal Fibrosis Through Immune Modulation and Remodeling Properties in a Rat Remnant Kidney Model , 2009, Stem cells.

[16]  D. Neuberg,et al.  Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy , 2009, Clinical Cancer Research.

[17]  G. Camussi,et al.  Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats , 2009, Journal of cellular and molecular medicine.

[18]  Alessandro Busca,et al.  Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  A. Cohen,et al.  Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. , 2009, Stem cells and development.

[20]  Jinkuk Kim,et al.  The role of mesenchymal stem cells in the functional improvement of chronic renal failure. , 2009, Stem cells and development.

[21]  W. Weimar,et al.  Potential of mesenchymal stem cells as immune therapy in solid‐organ transplantation , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[22]  D. Farber,et al.  Transfer of MicroRNAs by Embryonic Stem Cell Microvesicles , 2009, PloS one.

[23]  Jacopo Meldolesi,et al.  Shedding microvesicles: artefacts no more. , 2009, Trends in cell biology.

[24]  A. Falus,et al.  Highlights of a new type of intercellular communication: microvesicle-based information transfer , 2009, Inflammation Research.

[25]  J. Ryan,et al.  Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non‐redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells , 2008, Clinical and experimental immunology.

[26]  N. Perico,et al.  Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells1 , 2008, The Journal of Immunology.

[27]  N. Perico,et al.  Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice , 2008, Stem cells.

[28]  P. Veys,et al.  Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. , 2008, Blood.

[29]  P. Quesenberry,et al.  The Paradoxical Dynamism of Marrow Stem Cells: Considerations of Stem Cells, Niches, and Microvesicles , 2008, Stem Cell Reviews.

[30]  M. Yarmush,et al.  Mesenchymal stem cell–derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo , 2008, Hepatology.

[31]  I. Sargent,et al.  Microparticles and immunomodulation in pregnancy and pre-eclampsia. , 2007, Journal of reproductive immunology.

[32]  G. Remuzzi,et al.  Insulin-like growth factor-1 sustains stem cell mediated renal repair. , 2007, Journal of the American Society of Nephrology : JASN.

[33]  L. Noel,et al.  Intra Renal Arterial Injection of Autologous Mesenchymal Stem Cells in an Ovine Model in the Postischemic Kidney , 2007, Nephron Physiology.

[34]  Luigi Biancone,et al.  Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. , 2007, Blood.

[35]  M. Yarmush,et al.  Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure , 2007, PloS one.

[36]  L. Cantley,et al.  Stromal cells protect against acute tubular injury via an endocrine effect. , 2007, Journal of the American Society of Nephrology : JASN.

[37]  I. Stamenkovic,et al.  Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. , 2007, Kidney international.

[38]  D. Pisetsky,et al.  The Role of Microparticles in Inflammation and Thrombosis , 2007, Scandinavian journal of immunology.

[39]  P. Boor,et al.  Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. , 2007, Journal of the American Society of Nephrology : JASN.

[40]  Florian Tögel,et al.  Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. , 2007, American journal of physiology. Renal physiology.

[41]  G. Parmiani,et al.  Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.

[42]  P. M. Wang,et al.  Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. , 2007, Transplantation proceedings.

[43]  G. Camussi,et al.  Isolation and Characterization of a Stem Cell Population from Adult Human Liver , 2006, Stem cells.

[44]  J Ratajczak,et al.  Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication , 2006, Leukemia.

[45]  H. Anders,et al.  Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. , 2006, Kidney international.

[46]  A. Levine,et al.  The regulation of exosome secretion: a novel function of the p53 protein. , 2006, Cancer research.

[47]  J Ratajczak,et al.  Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery , 2006, Leukemia.

[48]  G. Camussi,et al.  Combined administration of G-CSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction. , 2006, Cytokine.

[49]  G. Garcia-Manero,et al.  The Cyclin-Dependent Kinase Inhibitor p57KIP2 Functions as a Tumor Suppressor Gene in Human Leukemia. , 2005 .

[50]  J. Duffield,et al.  Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. , 2005, Kidney international.

[51]  R. Schein,et al.  Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis , 2005, Critical care medicine.

[52]  A. Zander,et al.  Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. , 2005, Kidney international.

[53]  José A López,et al.  Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. , 2005, Blood.

[54]  L. Hsiao,et al.  Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. , 2005, The Journal of clinical investigation.

[55]  N. Caplice,et al.  Vascular progenitor cells: origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. , 2005, Stem cells and development.

[56]  Bing Li,et al.  Bone marrow cells contribute to regeneration of damaged glomerular endothelial cells. , 2005, Kidney international.

[57]  C. Lange,et al.  Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. , 2005, American journal of physiology. Renal physiology.

[58]  J. Freyssinet,et al.  Membrane microparticles: two sides of the coin. , 2005, Physiology.

[59]  G. Camussi,et al.  Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. , 2004, International journal of molecular medicine.

[60]  G. Camussi,et al.  Role of L-Selectin in the Vascular Homing of Peripheral Blood-Derived Endothelial Progenitor Cells1 , 2004, The Journal of Immunology.

[61]  M. Goligorsky,et al.  Adult skeletal muscle stem cells differentiate into endothelial lineage and ameliorate renal dysfunction after acute ischemia. , 2004, American journal of physiology. Renal physiology.

[62]  T. Rabelink,et al.  Progenitor cells in the kidney: biology and therapeutic perspectives. , 2004, Kidney international.

[63]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[64]  N. Perico,et al.  Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. , 2004, Journal of the American Society of Nephrology : JASN.

[65]  T. Shimazu,et al.  Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. , 2004, The Journal of trauma.

[66]  M. Krampera,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[67]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[68]  F. Kajiya,et al.  Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. , 2002, American journal of physiology. Renal physiology.

[69]  J. Cavaillon,et al.  Long‐term‐impaired expression of nuclear factor‐κB and IκBα in peripheral blood mononuclear cells of trauma patients , 2001, Journal of Leukocyte Biology.

[70]  J. Cavaillon,et al.  Interleukin-1 receptor antagonist production during infectious and noninfectious systemic inflammatory response syndrome , 2000, Critical care medicine.

[71]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[72]  K. Asadullah,et al.  Monocyte deactivation-rationale for a new therapeutic strategy in sepsis , 1996, Intensive Care Medicine.

[73]  L. Shapiro,et al.  Ciliary Neurotrophic Factor Combined with Soluble Receptor Inhibits Synthesis of Proinflammatory Cytokines and Prostaglandin-E2in Vitro , 1994 .

[74]  J. Mier,et al.  Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. , 1993, Journal of immunology.

[75]  J. Cavaillon,et al.  Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.

[76]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[77]  A. Leaf Cell Swelling: A Factor in Ischemic Tissue Injury , 1973, Circulation.

[78]  P. Siekevitz Biological membranes: the dynamics of their organization. , 1972, Annual Review of Physiology.

[79]  R. Malekzadeh,et al.  Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. , 2011, Archives of Iranian medicine.

[80]  Ciro Tetta,et al.  Exosome/microvesicle-mediated epigenetic reprogramming of cells. , 2011, American journal of cancer research.

[81]  Baharvand Hossein,et al.  AUTOLOGOUS TRANSPLANTATION OF BONE MARROW-DERIVED MONONUCLEAR AND CD133+ CELLS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS , 2011 .

[82]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[83]  H. K. Kim,et al.  Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. , 2003, European journal of cancer.

[84]  J. Cavaillon,et al.  Long-term-impaired expression of nuclear factor-kappa B and I kappa B alpha in peripheral blood mononuclear cells of trauma patients. , 2001, Journal of leukocyte biology.

[85]  J J Sixma,et al.  Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. , 1999, Blood.

[86]  L. Shapiro,et al.  Ciliary neurotrophic factor combined with soluble receptor inhibits synthesis of proinflammatory cytokines and prostaglandin-E2 in vitro. , 1994, Experimental cell research.

[87]  A. Leaf,et al.  The role of cell swelling in ischemic renal damage and the protective effect of hypertonic solute. , 1972, The Journal of clinical investigation.